Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis-Reference-Cited by-同舟云学术

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis

Published:2023-01-19 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Ruda Rachel C.¹^ORCID,Kelly Katherine A.¹,Feldman Steven R.¹²³⁴

Affiliation:

1. Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

2. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA

3. Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA

4. Department of Dermatology, University of Southern Denmark, Odense, Denmark

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2022.2140569

Reference32 articles.

2. U.S. Food and Drug Administration [Internet]. Purple Book Database of Licensed Biological Products. Silver Spring (MD): USFDA; 2021 [cited 2021 Nov 1]. Available from: https://purplebooksearch.fda.gov.

3. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems

5. U.S. Food and Drug Administration [Internet]. Scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring (MD): USFDA; 2015 [2021 Nov 1]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating adalimumab biosimilars: an expert opinion;Journal of Comparative Effectiveness Research;2023-11

2. Switching to biosimilars in dermatology: a patients’ perspective;Clinical and Experimental Dermatology;2023-09-14

3. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review;Dermatology and Therapy;2023-09-14

4. Durability and long-term outcomes of biologic therapies in psoriasis;Expert Review of Clinical Immunology;2023-08-25

5. Choosing Systemic Agents for Psoriasis;Annals of Pharmacotherapy;2023-06-21